Novartis AG (NVS)
NYSE • Healthcare
July 6, 2026 at 20:00 UTC
About Novartis AG
Novartis AG (NYSE: NVS) is a global pharmaceutical company in healthcare that develops and sells prescription drugs and related medicines, with $54.8 billion of revenue in FY2025. Its business spans innovative branded therapies, generic and biosimilar medicines, and manufacturing capabilities that reach patients, healthcare professionals, and other institutional buyers worldwide.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Novartis AG's Technical Indicators Summary
NVS trades around 155.49 and registers a predominantly bullish setup with price above short-, medium- and long-term moving averages and positive MACD and momentum readings, supporting the strong-buy classification. Trend strength is modest according to ADX, and volatility is contained, while on-balance volume is mixed and the pivot near 159.16 sits overhead as a near-term reference. These mixed volume and pivot signals temper the technical strength but the moving-average alignment remains constructive. Technical takeaway: Strong Buy.
| Indicator | Value |
|---|---|
RSI (14) | 55.09 |
Stochastic %K (14, 3, 3) | 75.21 |
CCI (20) | 76.37 |
WPR (14) | -36.36 |
Momentum (10) | 8.41 |
MFI | 69.18 |
MACD Level (12, 26) | 2.05 |
Bollinger Bands | $145.17 - $159.84 |
ATR (14) | $3.29 (2.11%) |
ADX (14) | 14.58 |
OBV | 14,655,327 |
Classic Pivot Point | $159.16 |
Fibonacci Pivot Point | $159.16 |
Exponential Moving Averages | $141.91 - $155.10(5 indicators) |
Simple Moving Averages | $143.65 - $154.99(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
A soft tone prevailed last session as NVS edged down to 159.90, shedding -2.76%.
Trading Volume
0
vs S&P 500 Today
Strong Underperformance
-5.13%
52-Week Position
Upper range
74.2%
Updated: July 7, 2026 at 12:05 UTC
Quote Summary
NVS Headlines
Novartis to acquire Myricx Bio for up to $1.5bn
July 6, 2026
Azoria ETFs shut, Novartis India stake sold, tariff shock
February 20, 2026
Live Nation, PTC, AES Lead Busy Earnings and Energy News
February 19, 2026
Avidity sets spin-off record date pre‑Novartis deal
February 3, 2026